Telaprevir triple combination therapy, and dual peginterferon α-2a/ribavirin therapy for 24 weeks for those with rapid-early response is not inferior to 48 weeks of therapy for treatment-naïve patients with genotype 1 hepatitis C virus infection. Issue 5 (31st January 2012)

Record Type:: Journal Article
Title:: Telaprevir triple combination therapy, and dual peginterferon α-2a/ribavirin therapy for 24 weeks for those with rapid-early response is not inferior to 48 weeks of therapy for treatment-naïve patients with genotype 1 hepatitis C virus infection. Issue 5 (31st January 2012)
Main Title:: Telaprevir triple combination therapy, and dual peginterferon α-2a/ribavirin therapy for 24 weeks for those with rapid-early response is not inferior to 48 weeks of therapy for treatment-naïve patients with genotype 1 hepatitis C virus infection
Authors:: Danta, Mark
Abstract:
Is Part Of:: Evidence-based medicine. Volume 17:Issue 5(2012)
Journal:: Evidence-based medicine
Issue:: Volume 17:Issue 5(2012)
Issue Display:: Volume 17, Issue 5 (2012)
Year:: 2012
Volume:: 17
Issue:: 5
Issue Sort Value:: 2012-0017-0005-0000
Page Start:: 143
Page End:: 144
Publication Date:: 2012-01-31
Subjects:: Evidence-based medicine -- Periodicals
616
Journal URLs:: http://ebm.bmj.com/ ↗
http://ebm.bmjjournals.com/ ↗
http://www.bmj.com/archive ↗
DOI:: 10.1136/ebmed-2011-100469 ↗
Languages:: English
ISSNs:: 1356-5524
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:: 19455.xml